WO2002032393A3 - Composition medicamenteuse et en particulier son utilisation dans la fluidotherapie - Google Patents

Composition medicamenteuse et en particulier son utilisation dans la fluidotherapie Download PDF

Info

Publication number
WO2002032393A3
WO2002032393A3 PCT/BE2001/000180 BE0100180W WO0232393A3 WO 2002032393 A3 WO2002032393 A3 WO 2002032393A3 BE 0100180 W BE0100180 W BE 0100180W WO 0232393 A3 WO0232393 A3 WO 0232393A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicinal composition
fluid therapy
molecule
supplying
sodium chloride
Prior art date
Application number
PCT/BE2001/000180
Other languages
English (en)
Other versions
WO2002032393A2 (fr
Inventor
Pascal Gustin
Carole Cambier
Thierry Clerbaux
Albert Frans
Bruno Detry
Original Assignee
Univ Liege
Univ Catholique Louvain
Pascal Gustin
Carole Cambier
Thierry Clerbaux
Albert Frans
Bruno Detry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege, Univ Catholique Louvain, Pascal Gustin, Carole Cambier, Thierry Clerbaux, Albert Frans, Bruno Detry filed Critical Univ Liege
Priority to AU9530101A priority Critical patent/AU9530101A/xx
Priority to ES01975890T priority patent/ES2238484T3/es
Priority to CA002425699A priority patent/CA2425699A1/fr
Priority to AT01975890T priority patent/ATE289820T1/de
Priority to EP01975890A priority patent/EP1326621B1/fr
Priority to DE60109184T priority patent/DE60109184T2/de
Priority to US10/398,780 priority patent/US20040033268A1/en
Publication of WO2002032393A2 publication Critical patent/WO2002032393A2/fr
Publication of WO2002032393A3 publication Critical patent/WO2002032393A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composition médicamenteuse comprenant, en quantités thérapeutiquement efficaces du chlorure de sodium hypertonique, au moins une molécule exerçant de manière directe ou indirecte un effet de relaxation des muscles lisses vasculaires, et au moins une molécule susceptible de fournir un apport exogène en phosphates.
PCT/BE2001/000180 2000-10-16 2001-10-16 Composition medicamenteuse et en particulier son utilisation dans la fluidotherapie WO2002032393A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU9530101A AU9530101A (en) 2000-10-16 2001-10-16 Medicinal composition and in particular its use in fluid therapy
ES01975890T ES2238484T3 (es) 2000-10-16 2001-10-16 Composicion medicamentosa y en especial su utilizacion en fluidoterapia.
CA002425699A CA2425699A1 (fr) 2000-10-16 2001-10-16 Composition medicamenteuse et en particulier son utilisation dans la fluidotherapie
AT01975890T ATE289820T1 (de) 2000-10-16 2001-10-16 Medizinische zusammensetzung und insbesondere seine verwendung in der flüssigkeitstherapie
EP01975890A EP1326621B1 (fr) 2000-10-16 2001-10-16 Composition medicamenteuse et en particulier son utilisation dans la fluidotherapie
DE60109184T DE60109184T2 (de) 2000-10-16 2001-10-16 Medizinische zusammensetzung und insbesondere seine verwendung in der flüssigkeitstherapie
US10/398,780 US20040033268A1 (en) 2000-10-16 2001-10-16 Medicinal composition and in particular its use in fluid therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00203619.2 2000-10-16
EP00203619 2000-10-16

Publications (2)

Publication Number Publication Date
WO2002032393A2 WO2002032393A2 (fr) 2002-04-25
WO2002032393A3 true WO2002032393A3 (fr) 2002-07-04

Family

ID=8172152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2001/000180 WO2002032393A2 (fr) 2000-10-16 2001-10-16 Composition medicamenteuse et en particulier son utilisation dans la fluidotherapie

Country Status (8)

Country Link
US (1) US20040033268A1 (fr)
EP (1) EP1326621B1 (fr)
AT (1) ATE289820T1 (fr)
AU (1) AU9530101A (fr)
CA (1) CA2425699A1 (fr)
DE (1) DE60109184T2 (fr)
ES (1) ES2238484T3 (fr)
WO (1) WO2002032393A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3820840C1 (en) * 1988-06-21 1989-11-09 Friedhelm Dr. 6200 Wiesbaden De Beyersdorf Aqueous reperfusion solution for reducing the reperfusion damage after acute peripheral vascular occlusion
FR2645746A1 (fr) * 1989-04-17 1990-10-19 Celtipharm Sarl Solute alcalinisant pour le traitement des acidoses metaboliques post-natales et diarrheiques des veaux
US5811463A (en) * 1993-10-06 1998-09-22 University Of British Columbia Compositions and method for relaxing smooth muscles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663289A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vitro use thereof
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US6063624A (en) * 1997-06-09 2000-05-16 Baxter International Inc. Platelet suspensions and methods for resuspending platelets

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3820840C1 (en) * 1988-06-21 1989-11-09 Friedhelm Dr. 6200 Wiesbaden De Beyersdorf Aqueous reperfusion solution for reducing the reperfusion damage after acute peripheral vascular occlusion
FR2645746A1 (fr) * 1989-04-17 1990-10-19 Celtipharm Sarl Solute alcalinisant pour le traitement des acidoses metaboliques post-natales et diarrheiques des veaux
US5811463A (en) * 1993-10-06 1998-09-22 University Of British Columbia Compositions and method for relaxing smooth muscles

Also Published As

Publication number Publication date
WO2002032393A2 (fr) 2002-04-25
ATE289820T1 (de) 2005-03-15
AU9530101A (en) 2002-04-29
EP1326621B1 (fr) 2005-03-02
US20040033268A1 (en) 2004-02-19
CA2425699A1 (fr) 2002-04-25
DE60109184D1 (de) 2005-04-07
ES2238484T3 (es) 2005-09-01
EP1326621A2 (fr) 2003-07-16
DE60109184T2 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
AU2459402A (en) Composition
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2004021968A3 (fr) Solution destinee a une application ungueale et peri-ungueale
EP1550456A3 (fr) Utilisation de la toxine botulinique dans le traitement des douleurs liées aux brûlures
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
WO1998030242A3 (fr) Compositions photochimiotherapeutiques
TW200504078A (en) Therapeutically active compounds and their use
AU1122202A (en) Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2003008637A3 (fr) Utilisation du genotypage dans l'individualisation des therapies
WO2004093813A3 (fr) Compositions renfermant un inhibiteur selectif a l'egard de la cyclooxygenase 2 et un agent de modulation du calcium pour le traitement de la douleur, de l'inflammation ou de troubles dus a l'inflammation
WO2002032393A3 (fr) Composition medicamenteuse et en particulier son utilisation dans la fluidotherapie
WO2003007876A3 (fr) Conjugues acide amine-acide gras normal et utilisations therapeutiques
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
WO2002039958A3 (fr) Therapies combinees a base de pentafluorobenzenesulfonamides et d'agents antineoplasiques
MD980129A (en) Antiherpetic remedy
WO2002036105A3 (fr) Utilisation d'agents sequestrants de cortisol dans le cadre du traitement de troubles lies a l'hypercortisolemie
ATE459376T1 (de) Pharmazeutische formulierung und darin enthaltende liganden; uea-1 mimetika
AU2001272552A1 (en) Oxygen-enriched agent and the use thereof for therapeutic purposes
EP1166779A3 (fr) Utilisation de nimesulide pour le traitement des maladies dermatologiques
HK1058305A1 (en) Combinations of dalfopristine/quinupristine with cefpirome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001975890

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2425699

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001975890

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10398780

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2001975890

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP